Eric W. Joseph

1.5k total citations · 1 hit paper
9 papers, 1.2k citations indexed

About

Eric W. Joseph is a scholar working on Molecular Biology, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Eric W. Joseph has authored 9 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 5 papers in Oncology and 3 papers in Pathology and Forensic Medicine. Recurrent topics in Eric W. Joseph's work include Melanoma and MAPK Pathways (6 papers), Cancer Mechanisms and Therapy (3 papers) and Computational Drug Discovery Methods (3 papers). Eric W. Joseph is often cited by papers focused on Melanoma and MAPK Pathways (6 papers), Cancer Mechanisms and Therapy (3 papers) and Computational Drug Discovery Methods (3 papers). Eric W. Joseph collaborates with scholars based in United States, Japan and United Kingdom. Eric W. Joseph's co-authors include Neal Rosen, Poulikos I. Poulikakos, Madhavi Tadi, Ensar Halilovic, Christine A. Pratilas, Piro Lito, Margaret K. Callahan, Sarat Chandarlapaty, Alan Huang and Taha Merghoub and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Cancer Cell and Cancer Research.

In The Last Decade

Eric W. Joseph

8 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Relief of Profound Feedback Inhibition of Mitogenic Signaling by RAF Inhibitors Attenuates Their Activity in BRAFV600E Melanomas

2012 410 citations Piro Lito, Christine A. Pratilas et al. Cancer Cell profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Eric W. Joseph United States	7	964	516	260	179	113	9	1.2k
Jahan Hussain United Kingdom	3	1.0k 1.1×	609 1.2×	203 0.8×	227 1.3×	85 0.8×	3	1.2k
Madhavi Tadi United States	7	849 0.9×	429 0.8×	175 0.7×	138 0.8×	70 0.6×	7	1.0k
Allison Marlow United States	3	724 0.8×	447 0.9×	166 0.6×	98 0.5×	137 1.2×	3	946
Carla Milagre United Kingdom	6	1.1k 1.2×	712 1.4×	204 0.8×	224 1.3×	109 1.0×	8	1.4k
Maureen R. Bleam United States	6	862 0.9×	548 1.1×	154 0.6×	166 0.9×	125 1.1×	13	1.1k
Charles Ng United States	10	962 1.0×	658 1.3×	177 0.7×	195 1.1×	81 0.7×	11	1.2k
Yogindra Persaud United States	6	619 0.6×	368 0.7×	136 0.5×	105 0.6×	151 1.3×	12	818
Jose Lobo United States	8	1.2k 1.3×	758 1.5×	236 0.9×	169 0.9×	276 2.4×	8	1.6k
Leanne Berry United States	14	1.2k 1.2×	715 1.4×	182 0.7×	115 0.6×	268 2.4×	24	1.7k
Patrícia Volpe United States	4	963 1.0×	639 1.2×	157 0.6×	108 0.6×	223 2.0×	6	1.3k

Countries citing papers authored by Eric W. Joseph

Since Specialization

Citations

This map shows the geographic impact of Eric W. Joseph's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric W. Joseph with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric W. Joseph more than expected).

Fields of papers citing papers by Eric W. Joseph

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eric W. Joseph. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric W. Joseph. The network helps show where Eric W. Joseph may publish in the future.

Co-authorship network of co-authors of Eric W. Joseph

This figure shows the co-authorship network connecting the top 25 collaborators of Eric W. Joseph. A scholar is included among the top collaborators of Eric W. Joseph based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eric W. Joseph. Eric W. Joseph is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

1.

Sangro, Bruno, Masatoshi Kudo, Shukui Qin, et al.. (2020). P-347 A phase 3, randomized, double-blind, placebo-controlled study of transarterial chemoembolization combined with durvalumab or durvalumab plus bevacizumab therapy in patients with locoregional hepatocellular carcinoma: EMERALD-1. Annals of Oncology. 31. S202–S203. 30 indexed citations

2.

Lito, Piro, Anna Saborowski, Jingyin Yue, et al.. (2014). Disruption of CRAF-Mediated MEK Activation Is Required for Effective MEK Inhibition in KRAS Mutant Tumors. Cancer Cell. 25(5). 697–710. 222 indexed citations

3.

Lito, Piro, Anna Saborowski, Jingyin Yue, et al.. (2014). Abstract 4758: Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors. Cancer Research. 74(19_Supplement). 4758–4758. 1 indexed citations

4.

Ishii, Nobuya, Naoki Harada, Eric W. Joseph, et al.. (2013). Enhanced Inhibition of ERK Signaling by a Novel Allosteric MEK Inhibitor, CH5126766, That Suppresses Feedback Reactivation of RAF Activity. Cancer Research. 73(13). 4050–4060. 128 indexed citations

5.

Zhang, Qing‐Shuo, Andrea M. Sheehan, Kevin Watanabe‐Smith, et al.. (2013). Evaluation of resveratrol and N‐acetylcysteine for cancer chemoprevention in a Fanconi anemia murine model. Pediatric Blood & Cancer. 61(4). 740–742. 12 indexed citations

6.

Zhang, Qing‐Shuo, Kevin Watanabe‐Smith, Kathryn Schubert, et al.. (2013). Fancd2 and p21 function independently in maintaining the size of hematopoietic stem and progenitor cell pool in mice. Stem Cell Research. 11(2). 687–692. 8 indexed citations

7.

Lito, Piro, Christine A. Pratilas, Eric W. Joseph, et al.. (2012). Relief of Profound Feedback Inhibition of Mitogenic Signaling by RAF Inhibitors Attenuates Their Activity in BRAFV600E Melanomas. Cancer Cell. 22(5). 668–682. 410 indexed citations breakdown →

8.

Poulikakos, Poulikos I., Yogindra Persaud, Manickam Janakiraman, et al.. (2011). Abstract LB-419: An in-frame deletion in the N-terminal regulatory domain of BRAF(V600E) causes resistance to the RAF inhibitor PLX4032. Cancer Research. 71(8_Supplement). LB–419.

9.

Joseph, Eric W., Christine A. Pratilas, Poulikos I. Poulikakos, et al.. (2010). The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proceedings of the National Academy of Sciences. 107(33). 14903–14908. 349 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact